NCT05638867View on ClinicalTrials.gov

NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

PHASE4RecruitingINTERVENTIONAL
Enrollment

3,944

Participants

Timeline

Start Date

November 25, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Coronary Artery DiseasePercutaneous Coronary InterventionAcute Coronary Syndrome
Interventions
DRUG

Aspirin + Clopidogrel + Rivaroxaban

Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily

DRUG

Aspirin + Clopidogrel

Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily

Trial Locations (1)

100037

RECRUITING

Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV